Collectively, these data demonstrate that disrupting PTN–PTPRZ1 signalling by the anti-PTPRZ1 antibody impairs the supportive effect of TAMs, thus potently suppresses GSC tumour growth. Here, PTPRZ1 is linked to neoplasm.